Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-123 in Sepsis and Coagulopathy
NCT03517501Phase 3Withdrawn
- Sponsor
- Asahi Kasei Corporation
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of thrombomodulin alfa in sepsis, coagulopathy, sponsored by Asahi Kasei Corporation. Planned start Jul 2019; status: withdrawn.
02
Drugs
thrombomodulin alfa
03
Conditions
sepsiscoagulopathy
Beyond the preview
Go deeper on NCT03517501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517501.